{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:19:15Z","timestamp":1790392755859,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previous findings suggested that a four-protein complex, including sterol-regulatory element-binding protein (SREBP), SREBP-cleavage-activating protein (SCAP), insulin-induced gene (INSIG) and progesterone receptor membrane component 1 (PGRMC1), within the endoplasmic reticulum appears to be an important regulator responsible for atypical antipsychotic drug (AAPD)-induced lipid disturbances. In the present study, effects of typical antipsychotic drug and AAPDs as well as treatment outcome of steroid antagonist mifepristone (MIF) on the PGRMC1\/INSIG\/SCAP\/SREBP pathway were investigated in rat liver using real-time quantitative polymerase chain reaction (qPCR) and western blot analysis. In addition, serum triacylglycerol, total cholesterol, free fatty acids and various hormones including progesterone, corticosterone and insulin were measured simultaneously. Following treatment with clozapine or risperidone, both lipogenesis and cholesterogenesis were enhanced via inhibition of PGRMC1\/INSIG-2 and activation of SCAP\/SREBP expressions. Such metabolic disturbances, however, were not demonstrated in rats treated with aripiprazole (ARI) or haloperidol (HAL). Moreover, the add-on treatment of MIF was effective in reversing the AAPD-induced lipid disturbances by upregulating the expression of PGRMC1\/INSIG-2 and subsequent downregulation of SCAP\/SREBP. Taken together, our findings suggest that disturbances in lipid metabolism can occur at an early stage of AAPD treatment before the presence of weight gain. Such metabolic defects can be modified by an add-on treatment of steroid antagonist MIF enhancing the PGRMC1 pathway. Thus, it is likely that PGRMC1\/INSIG-2 signaling may be a therapeutic target for AAPD-induced weight gain.<\/jats:p>","DOI":"10.1038\/tp.2015.161","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T13:45:12Z","timestamp":1445348712000},"page":"e661-e661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["A potential mechanism underlying atypical antipsychotics-induced lipid disturbances"],"prefix":"10.1038","volume":"5","author":[{"given":"H L","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q Y","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H D","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"key":"BFtp2015161_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","volume":"101","author":"M De Hert","year":"2008","unstructured":"De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295\u2013303.","journal-title":"Schizophr Res"},{"key":"BFtp2015161_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","volume":"8","author":"M De Hert","year":"2009","unstructured":"De Hert M, Schreurs V, Vancampfort D, Van Winkel R . Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8: 15\u201322.","journal-title":"World Psychiatry"},{"key":"BFtp2015161_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71\u201393.","journal-title":"Schizophr Bull"},{"key":"BFtp2015161_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/1359786806066040","volume":"20","author":"GP Reynolds","year":"2006","unstructured":"Reynolds GP, Hill MJ, Kirk SL . The 5-HT2C receptor and antipsychotic induced weight gain\u2013mechanisms and genetics. J Psychopharmacol 2006; 20: 15\u201318.","journal-title":"J Psychopharmacol"},{"key":"BFtp2015161_CR5","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"SF Kim","year":"2007","unstructured":"Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH . From the Cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007; 104: 3456\u20133459.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtp2015161_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/clp.11.67","volume":"7","author":"AK Walker","year":"2012","unstructured":"Walker AK, Naar AM . SREBPs: regulators of cholesterol\/lipids as therapeutic targets in metabolic disorders, cancers and viral diseases. Clin Lipidol 2012; 7: 27\u201336.","journal-title":"Clin Lipidol"},{"key":"BFtp2015161_CR7","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/j.peptides.2010.07.020","volume":"31","author":"XY Dong","year":"2010","unstructured":"Dong XY, Tang SQ . Insulin-induced gene: a new regulator in lipid metabolism. Peptides 2010; 31: 2145\u20132150.","journal-title":"Peptides"},{"key":"BFtp2015161_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2005.12.022","volume":"124","author":"JL Goldstein","year":"2006","unstructured":"Goldstein JL, DeBose-Boyd RA, Brown MS . Protein sensors for membrane sterols. Cell 2006; 124: 35\u201346.","journal-title":"Cell"},{"key":"BFtp2015161_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.mp.4002133","volume":"14","author":"S Le Hellard","year":"2009","unstructured":"Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fern\u00f8 J, Gebhardt S et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol. Psychiatry 2009; 14: 308\u2013317.","journal-title":"Mol. Psychiatry"},{"key":"BFtp2015161_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/tpj.2010.74","volume":"12","author":"YJ Liou","year":"2012","unstructured":"Liou YJ, Bai YM, Lin E, Chen JY, Chen TT, Hong CJ et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J 2012; 12: 54\u201361.","journal-title":"Pharmacogenomics J"},{"key":"BFtp2015161_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00210-010-0499-4","volume":"381","author":"E Lauressergues","year":"2010","unstructured":"Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 427\u2013439.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFtp2015161_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-010-0597-3","volume":"383","author":"E Lauressergues","year":"2011","unstructured":"Lauressergues E, Martin F, Helleboid A, Bouchaert E, Cussac D, Bordet R et al. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 423\u2013436.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFtp2015161_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.tpj.6500323","volume":"5","author":"J Fern\u00f8","year":"2005","unstructured":"Fern\u00f8 J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 2005; 5: 298\u2013304.","journal-title":"Pharmacogenomics J"},{"key":"BFtp2015161_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","volume":"203","author":"J Fern\u00f8","year":"2009","unstructured":"Fern\u00f8 J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009; 203: 73\u201384.","journal-title":"Psychopharmacology"},{"key":"BFtp2015161_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00213-011-2397-y","volume":"219","author":"G Jassim","year":"2012","unstructured":"Jassim G, Skrede S, V\u00e1zquez MJ, Wergedal H, Vik-Mo AO, Lunder N et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology 2012; 219: 783\u2013794.","journal-title":"Psychopharmacology"},{"key":"BFtp2015161_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nmeth752","volume":"2","author":"M Suchanek","year":"2005","unstructured":"Suchanek M, Radzikowska A, Thiele C . Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells. Nat Methods 2005; 2: 261\u2013267.","journal-title":"Nat Methods"},{"key":"BFtp2015161_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.steroids.2007.12.017","volume":"73","author":"RM Losel","year":"2008","unstructured":"Losel RM, Besong D, Peluso JJ, Wehling M . Progesterone receptor membrane component 1\u2014many tasks for a versatile protein. Steroids 2008; 73: 929\u2013934.","journal-title":"Steroids"},{"key":"BFtp2015161_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pharmthera.2008.09.006","volume":"121","author":"HJ Rohe","year":"2009","unstructured":"Rohe HJ, Ahmed IS, Twist KE, Craven RJ . PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 2009; 121: 14\u201319.","journal-title":"Pharmacol Ther"},{"key":"BFtp2015161_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1432-1033.1996.0726u.x","volume":"239","author":"C Meyer","year":"1996","unstructured":"Meyer C, Schmid R, Scriba PC, Wehling M . Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996; 239: 726\u2013731.","journal-title":"Eur J Biochem"},{"key":"BFtp2015161_CR20","doi-asserted-by":"publisher","first-page":"12816","DOI":"10.1073\/pnas.97.23.12816","volume":"97","author":"CJ Krebs","year":"2000","unstructured":"Krebs CJ, Jarvis ED, Chan J, Lydon JP, Ogawa S, Pfaff DW et al. A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proc Natl Acad Sci USA 2000; 97: 12816\u201312821.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtp2015161_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bbr.2006.03.039","volume":"171","author":"KL Beebe","year":"2006","unstructured":"Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK . The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res 2006; 171: 225\u2013229.","journal-title":"Behav Brain Res"},{"key":"BFtp2015161_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12325-009-0070-1","volume":"26","author":"C Gross","year":"2009","unstructured":"Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK . Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 2009; 26: 959\u2013969.","journal-title":"Adv Ther"},{"key":"BFtp2015161_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/oby.2010.51","volume":"18","author":"C Gross","year":"2010","unstructured":"Gross C, Blasey CM, Roe RL, Belanoff JK . Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity 2010; 18: 2295\u20132300.","journal-title":"Obesity"},{"key":"BFtp2015161_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2007","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J 2007; 22: 659\u2013661.","journal-title":"FASEB J"},{"key":"BFtp2015161_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/B978-0-444-59499-0.00002-7","volume":"34","author":"HN Chan","year":"2012","unstructured":"Chan HN, Mitchell PB . 2 Antidepressant drugs. Side Effects Drugs Annu 2012; 34: 17.","journal-title":"Side Effects Drugs Annu"},{"key":"BFtp2015161_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1192\/bjp.166.6.712","volume":"166","author":"J Peuskens","year":"1995","unstructured":"Peuskens J . Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712\u2013726.","journal-title":"Br J Psychiatry"},{"key":"BFtp2015161_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2165\/11310820-000000000-00000","volume":"23","author":"S Mace","year":"2009","unstructured":"Mace S, Taylor D . Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009; 23: 773\u2013780.","journal-title":"CNS Drugs"},{"key":"BFtp2015161_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/schbul\/21.4.593","volume":"21","author":"D Umbricht","year":"1995","unstructured":"Umbricht D, Kane JM . Risperidone: efficacy and safety. Schizophr Bull 1995; 21: 593\u2013606.","journal-title":"Schizophr Bull"},{"key":"BFtp2015161_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1017\/S1461145710000490","volume":"13","author":"WW Fleischhacker","year":"2010","unstructured":"Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115\u20131125.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtp2015161_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2144\/000112401","volume":"42","author":"AB Human","year":"2007","unstructured":"Human AB, Lim SR, Difilippantonio MJ, Ried T . Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. Biotechniques 2007; 42: 467\u2013472.","journal-title":"Biotechniques"},{"key":"BFtp2015161_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248\u2013254.","journal-title":"Anal Biochem"},{"key":"BFtp2015161_CR32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007; 447: 1081\u20131086.","journal-title":"Nature"},{"key":"BFtp2015161_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","volume":"75","author":"B Pouzet","year":"2003","unstructured":"Pouzet B, Mow T, Kreilgaard M, Velschow S . Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003; 75: 133\u2013140.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp2015161_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000100981","volume":"85","author":"G Tulipano","year":"2007","unstructured":"Tulipano G, Rizzetti C, Bianchi I, Fanzani A, Spano P, Cocchi D . Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 2007; 85: 61\u201370.","journal-title":"Neuroendocrinology"},{"key":"BFtp2015161_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0091-3057(87)90340-6","volume":"27","author":"T Baptista","year":"1987","unstructured":"Baptista T, Parada M, Hernandez L . Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 1987; 27: 399\u2013405.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp2015161_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0091-3057(93)90084-7","volume":"45","author":"T Baptista","year":"1993","unstructured":"Baptista T, Mata A, Teneud L, de Quijada M, Han HW, Hern\u00e1ndez L . Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 1993; 45: 51\u201354.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp2015161_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0278-5846(01)00266-4","volume":"26","author":"G Kaur","year":"2002","unstructured":"Kaur G, Kulkarni SK . Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 277\u2013285.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtp2015161_CR38","first-page":"121","volume":"152","author":"AA Arjona","year":"2004","unstructured":"Arjona AA, Zhang SX, Adamson B, Wurtman RJ . An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004; 152: 121\u2013127.","journal-title":"Behav Brain Res"},{"key":"BFtp2015161_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","volume":"125","author":"GP Reynolds","year":"2010","unstructured":"Reynolds GP, Kirk SL . Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms. Pharmacol Ther 2010; 125: 169\u2013179.","journal-title":"Pharmacol Ther"},{"key":"BFtp2015161_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","volume":"34","author":"HN Boyda","year":"2010","unstructured":"Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 945\u2013954.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtp2015161_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cmet.2005.09.002","volume":"2","author":"MW Hulver","year":"2005","unstructured":"Hulver MW, Berggren JR, Carper MJ, Miyazaki M, Ntambi JM, Hoffman EP et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab 2005; 2: 251\u2013261.","journal-title":"Cell Metab"},{"key":"BFtp2015161_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.schres.2008.11.025","volume":"108","author":"MH Polymeropoulos","year":"2009","unstructured":"Polymeropoulos MH, Licamele L, Volpi S, Mack K, Mitkus SN, Carstea ED et al. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr Res 2009; 108: 134\u2013142.","journal-title":"Schizophr Res"},{"key":"BFtp2015161_CR43","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1017\/S1461145708008468","volume":"11","author":"AO Vik-Mo","year":"2008","unstructured":"Vik-Mo AO, Birkenaes AB, Fern\u00f8 J, Jonsdottir H, Andreassen OA, Steen VM . Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008; 11: 679\u2013684.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtp2015161_CR44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cmet.2011.12.017","volume":"15","author":"YA Moon","year":"2012","unstructured":"Moon YA, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V et al. The Scap\/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 2012; 15: 240\u2013246.","journal-title":"Cell Metab"},{"key":"BFtp2015161_CR45","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1073\/pnas.0130116100","volume":"100","author":"D Yabe","year":"2003","unstructured":"Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS . Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc Natl Acad Sci USA 2003; 100: 3155\u20133160.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtp2015161_CR46","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1210\/endo.142.4.8114","volume":"142","author":"JR Seckl","year":"2001","unstructured":"Seckl JR, Walker BR . Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371\u20131376.","journal-title":"Endocrinology"},{"key":"BFtp2015161_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1196\/annals.1367.012","volume":"1083","author":"BR Walker","year":"2006","unstructured":"Walker BR, Andrew R . Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci 2006; 1083: 165\u2013184.","journal-title":"Ann N Y Acad Sci"},{"key":"BFtp2015161_CR48","first-page":"R539","volume":"259","author":"SC Langley","year":"1990","unstructured":"Langley SC, York DA . Effects of antiglucocorticoid RU 486 on development of obesity in obese fa\/fa Zucker rats. Am J Physiol 1990; 259: R539\u2013R544.","journal-title":"Am J Physiol"},{"key":"BFtp2015161_CR49","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.1073\/pnas.0401715101","volume":"101","author":"K Takaishi","year":"2004","unstructured":"Takaishi K, Duplomb L, Wang MY, Li J, Unger RH . Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted\/refed normal rats. Proc Natl Acad Sci USA 2004; 101: 7106\u20137111.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tp2015161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2015161","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2015161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:57:15Z","timestamp":1672912635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp2015161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"alternative-id":["BFtp2015161"],"URL":"https:\/\/doi.org\/10.1038\/tp.2015.161","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]},"assertion":[{"value":"27 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}